诺诚健华迎来转折点。2025 年第一季度，诺诚健华实现总营收 3.81 亿元，同比增长 129.92%，净利润为 1796.76 万元，成功扭亏为盈。截至 2025 年 3 月 31 日，诺诚健华持有现金及相关账户结余约 77.8 亿元。这份财报背后，是一个关于创新、战略与耐心的生存启示录……大单品的威力大单品，是 Biotech 穿越寒冬的“诺亚方舟”，更是反攻的冲锋号角。例如，贝达药业的埃克...
Source Link诺诚健华迎来转折点。2025 年第一季度，诺诚健华实现总营收 3.81 亿元，同比增长 129.92%，净利润为 1796.76 万元，成功扭亏为盈。截至 2025 年 3 月 31 日，诺诚健华持有现金及相关账户结余约 77.8 亿元。这份财报背后，是一个关于创新、战略与耐心的生存启示录……大单品的威力大单品，是 Biotech 穿越寒冬的“诺亚方舟”，更是反攻的冲锋号角。例如，贝达药业的埃克...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.